HRP20130447T1 - Pharmaceutical composition with prolonged release of octreotide acetate - Google Patents
Pharmaceutical composition with prolonged release of octreotide acetateInfo
- Publication number
- HRP20130447T1 HRP20130447T1 HRP20130447AT HRP20130447T HRP20130447T1 HR P20130447 T1 HRP20130447 T1 HR P20130447T1 HR P20130447A T HRP20130447A T HR P20130447AT HR P20130447 T HRP20130447 T HR P20130447T HR P20130447 T1 HRP20130447 T1 HR P20130447T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutical composition
- prolonged release
- octreotide acetate
- octreotide
- acetate
- Prior art date
Links
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 title 1
- 108010016076 Octreotide Proteins 0.000 title 1
- 229960001494 octreotide acetate Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000002035 prolonged effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200703103A ES2324009B1 (es) | 2007-11-23 | 2007-11-23 | Composicion farmaceutica de liberacion sostenida de somatostatina o un analogo suyo. |
| PCT/ES2008/000731 WO2009068708A2 (es) | 2007-11-23 | 2008-11-21 | Composición farmacéutica de liberación sostenida de somatostatina o un análogo suyo |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20130447T1 true HRP20130447T1 (en) | 2013-06-30 |
Family
ID=40589822
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20130447AT HRP20130447T1 (en) | 2007-11-23 | 2013-05-22 | Pharmaceutical composition with prolonged release of octreotide acetate |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20110124563A1 (hr) |
| EP (1) | EP2223684B1 (hr) |
| AR (1) | AR069420A1 (hr) |
| CL (1) | CL2008003489A1 (hr) |
| CY (1) | CY1114045T1 (hr) |
| DK (1) | DK2223684T3 (hr) |
| ES (2) | ES2324009B1 (hr) |
| HR (1) | HRP20130447T1 (hr) |
| PL (1) | PL2223684T3 (hr) |
| PT (1) | PT2223684E (hr) |
| SI (1) | SI2223684T1 (hr) |
| TW (1) | TWI463991B (hr) |
| WO (1) | WO2009068708A2 (hr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR106085A1 (es) | 2015-09-21 | 2017-12-13 | Teva Pharmaceuticals Int Gmbh | Formulaciones de olanzapina de liberación sostenida |
| US11266608B2 (en) | 2015-09-25 | 2022-03-08 | Jennifer J. Kang-Mteler | Biodegradable extended release microsphere-hydrogel ocular drug delivery system and method |
| US10980882B2 (en) * | 2015-09-25 | 2021-04-20 | Jennifer J. KANG-MIELER | Biodegradable microsphere-hydrogel ocular drug delivery system |
| CA3057438A1 (en) | 2017-03-20 | 2018-09-27 | Teva Pharmaceuticals International Gmbh | Sustained release olanzapine formulaitons |
| WO2019016233A1 (en) | 2017-07-17 | 2019-01-24 | Medincell | PHARMACEUTICAL COMPOSITION |
| FR3079421A1 (fr) * | 2018-03-28 | 2019-10-04 | Edix Sa | Presentations injectables, seringues et compositions a liberation prolongee et/ou controlee de lanreotide |
| US20240100012A1 (en) | 2021-01-18 | 2024-03-28 | Mark Hasleton | Pharmaceutical dosage form |
| US20240277654A1 (en) | 2021-07-06 | 2024-08-22 | Mark Hasleton | Treatment of serotonin reuptake inhibitor withdrawal syndrome |
| CA3236834A1 (en) * | 2021-11-22 | 2023-05-25 | SpecGx LLC | Injectable sustained release pharmaceutical composition |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE61935T1 (de) * | 1985-02-07 | 1991-04-15 | Takeda Chemical Industries Ltd | Verfahren zur herstellung von mikrokapseln. |
| US5538739A (en) * | 1989-07-07 | 1996-07-23 | Sandoz Ltd. | Sustained release formulations of water soluble peptides |
| SE9100610D0 (sv) * | 1991-03-04 | 1991-03-04 | Procordia Ortech Ab | Bioresorbable material for medical use |
| US5980945A (en) * | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
| US6214792B1 (en) * | 1996-04-12 | 2001-04-10 | David Lew Simon | Method for treating acute and severe diarrhea |
| DE19621533A1 (de) * | 1996-05-29 | 1997-12-04 | Bosch Gmbh Robert | Elektromotorische Bremsvorrichtung |
| US6150333A (en) * | 1998-07-30 | 2000-11-21 | Biomeasure, Inc. | Methods of using a somatostatin analogue |
| ES2169980B1 (es) * | 1999-12-17 | 2003-11-01 | Lipotec Sa | Microcapsulas para la liberacion prolongada de farmacos. |
| KR100466637B1 (ko) * | 2003-06-26 | 2005-01-13 | 주식회사 펩트론 | 서방성 미립구의 혼합 제형을 연속한 단일 공정으로제조하는 방법 |
| US8871269B2 (en) * | 2003-07-15 | 2014-10-28 | Evonik Corporation | Method for the preparation of controlled release formulations |
| WO2007071395A1 (en) * | 2005-12-22 | 2007-06-28 | Novartis Ag | Sustained release formulation comprising octreotide and two or more polylactide-co-glycolide polymers |
-
2007
- 2007-11-23 ES ES200703103A patent/ES2324009B1/es active Active
-
2008
- 2008-11-21 TW TW097145180A patent/TWI463991B/zh not_active IP Right Cessation
- 2008-11-21 US US12/744,106 patent/US20110124563A1/en not_active Abandoned
- 2008-11-21 PT PT88556386T patent/PT2223684E/pt unknown
- 2008-11-21 EP EP08855638A patent/EP2223684B1/en not_active Not-in-force
- 2008-11-21 DK DK08855638.6T patent/DK2223684T3/da active
- 2008-11-21 ES ES08855638T patent/ES2414472T3/es active Active
- 2008-11-21 WO PCT/ES2008/000731 patent/WO2009068708A2/es active Application Filing
- 2008-11-21 SI SI200830961T patent/SI2223684T1/sl unknown
- 2008-11-21 PL PL08855638T patent/PL2223684T3/pl unknown
- 2008-11-24 AR ARP080105093A patent/AR069420A1/es unknown
- 2008-11-24 CL CL2008003489A patent/CL2008003489A1/es unknown
-
2013
- 2013-05-22 HR HRP20130447AT patent/HRP20130447T1/hr unknown
- 2013-06-11 CY CY20131100458T patent/CY1114045T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2223684A2 (en) | 2010-09-01 |
| TWI463991B (zh) | 2014-12-11 |
| WO2009068708A3 (es) | 2009-07-16 |
| US20110124563A1 (en) | 2011-05-26 |
| CL2008003489A1 (es) | 2009-05-29 |
| TW200936157A (en) | 2009-09-01 |
| ES2324009B1 (es) | 2010-05-21 |
| CY1114045T1 (el) | 2016-07-27 |
| WO2009068708A2 (es) | 2009-06-04 |
| EP2223684B1 (en) | 2013-03-27 |
| PT2223684E (pt) | 2013-06-20 |
| ES2414472T3 (es) | 2013-07-19 |
| DK2223684T3 (da) | 2013-06-17 |
| AR069420A1 (es) | 2010-01-20 |
| ES2324009A1 (es) | 2009-07-28 |
| SI2223684T1 (sl) | 2013-07-31 |
| PL2223684T3 (pl) | 2013-08-30 |
| WO2009068708A8 (es) | 2010-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL275854A (en) | Pharmaceutical composition and its administration | |
| HK1216232A1 (zh) | 控釋藥物組合物 | |
| HRP20130447T1 (en) | Pharmaceutical composition with prolonged release of octreotide acetate | |
| ZA200908019B (en) | Controlled release pharmaceutical compositions for prolonged effect | |
| EP2133094A4 (en) | PHARMACEUTICAL COMPOSITION | |
| EP2591773A4 (en) | TEMPORARY RELEASED PHARMACEUTICAL COMPOSITION WITH DAPOXIN FOR ORAL ADMINISTRATION | |
| EP2236149A4 (en) | MEDICAL COMPOSITION | |
| EP2226071A4 (en) | COMPOSITIONS FOR ORAL ADMINISTRATION | |
| AP2920A (en) | Anti-malarial pharmaceutical composition | |
| HK1162936A1 (en) | Solid pharmaceutical formulation with delayed release | |
| ZA201102715B (en) | Solid pharmaceutical composition | |
| ZA201100871B (en) | Solid pharmaceutical composition | |
| EP2327406A4 (en) | STABILIZED PHARMACEUTICAL COMPOSITION | |
| ZA201102405B (en) | Pharmaceutical composition for oral administration | |
| HK1182939A1 (en) | Stable pharmaceutical composition | |
| IL178378A0 (en) | Extended release pharmaceutical compositions | |
| HU0700172D0 (en) | Sustained release pharmaceutical preparation | |
| ZA201001127B (en) | Pharmaceutical formulation for extended release | |
| IL198994A0 (en) | Use of incensole and incensole acetate for the preparation of pharmaceutical compositions |